Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-01 02:18 | 2025-03-27 | SLNO | SOLENO THERAPEUTICS INC | Huang Michael F. | Officer | OPT+S | $69.51 | 14,583 | $1,013,626 | 36,817 |
| 2025-04-01 02:01 | 2025-03-27 | SLNO | SOLENO THERAPEUTICS INC | Hirano Patricia C | Officer | OPT+S | $68.51 | 156,315 | $10,709,359 | 30,818 |
| 2025-04-01 02:00 | 2025-03-27 | SLNO | SOLENO THERAPEUTICS INC | Anish Bhatnagar | Director, Officer | OPT+S | $67.62 | 699,095 | $47,271,965 | 577,076 |
| 2025-04-01 03:05 | 2025-03-28 | ZVRA | ZEVRA THERAPEUTICS, INC. | Watton Corey Michael | Director | BUY | $7.84 | 300 | $2,352 | 1,800 |
| 2025-04-01 02:20 | 2025-03-27 | SLNO | SOLENO THERAPEUTICS INC | Mackaness James H | Officer | OPT+S | $69.44 | 90,622 | $6,293,181 | 105,176 |
| 2025-03-31 16:18 | 2025-03-27 | RZLT | Rezolute, Inc. | Elam Nevan C | Director, Officer | BUY | $2.85 | 12,302 | $34,999 | 224,119 |
| 2025-03-31 23:04 | 2025-03-31 | GOVX | GeoVax Labs, Inc. | Reynolds Mark | Officer | BUY | $1.08 | 6,800 | $7,343 | 14,013 |
| 2025-03-31 23:28 | 2025-03-31 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer | SELL | $40.75 | 15,000 | $611,250 | 427,629 |
| 2025-03-28 23:45 | 2025-03-27 | NUVL | Nuvalent, Inc. | Noci Darlene | Officer | OPT+S | $73.12 | 4,000 | $292,468 | 48,034 |
| 2025-03-29 00:25 | 2025-03-21 | IBO | IMPACT BIOMEDICAL INC. | DSS, INC. | 10% owner | SELL | $3.22 | 605,620 | $1,950,944 | 1,051,800 |
| 2025-03-29 01:06 | 2025-03-26 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.44 | 15,000 | $6,656 | 399,272 |
| 2025-03-29 00:18 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Kling Douglas F | Officer | OPT+S | $0.00 | 16,539 | $0 | 44,000 |
| 2025-03-29 00:15 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Davidson Michael H. | Director, Officer | OPT+S | $0.00 | 12,258 | $0 | 390,441 |
| 2025-03-29 01:59 | 2025-03-27 | EOLS | Evolus, Inc. | MOATAZEDI DAVID | Director, Officer | SELL | $12.40 | 6,251 | $77,512 | 508,619 |
| 2025-03-28 23:51 | 2025-03-26 | BNTC | Benitec Biopharma Inc. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director, 10% owner | BUY | $13.00 | 900,000 | $11,700,000 | 1,066,764 |
| 2025-03-28 23:00 | 2025-03-26 | ATOS | ATOSSA THERAPEUTICS, INC. | Remmel H. Lawrence | Director | BUY | $0.70 | 10,000 | $7,000 | 10,257 |
| 2025-03-29 02:03 | 2025-03-26 | SLNO | SOLENO THERAPEUTICS INC | Vivo Opportunity, LLC | 10% owner | SELL | $67.87 | 1,833,557 | $124,449,198 | 4,458,294 |
| 2025-03-28 15:40 | 2025-03-26 | RZLT | Rezolute, Inc. | Evans Daron | Officer | BUY | $2.89 | 20,000 | $57,700 | 23,000 |
| 2025-03-29 00:22 | 2025-03-28 | OPK | OPKO HEALTH, INC. | FROST PHILLIP MD ET AL | Director, Officer, 10% owner | BUY | $1.70 | 150,000 | $254,385 | 213,651,448 |
| 2025-03-29 00:36 | 2025-03-26 | NAMS | NewAmsterdam Pharma Co N.V. | Topper James N | Director | BUY | $22.49 | 1,135 | $25,521 | 3,013,569 |
| 2025-03-28 02:42 | 2025-03-25 | AKRO | Akero Therapeutics, Inc. | Graham G. Walmsley | Director | BUY | $43.94 | 200,000 | $8,787,920 | 1,200,000 |
| 2025-03-27 23:54 | 2025-03-25 | BBIO | BridgeBio Pharma, Inc. | Kumar Neil | Director, Officer | SELL | $36.87 | 75,000 | $2,764,943 | 4,948,447 |
| 2025-03-27 23:40 | 2025-03-25 | PRLD | Prelude Therapeutics Inc | Combs Andrew | Officer | BUY | $0.69 | 100,000 | $69,250 | 480,123 |
| 2025-03-27 23:37 | 2025-03-25 | PRLD | Prelude Therapeutics Inc | Vaddi Krishna | Director, Officer | BUY | $0.69 | 675,000 | $467,438 | 1,999,296 |
| 2025-03-27 16:56 | 2025-03-17 | ZOM | Zomedica Corp. | Rowe Jeffrey M | Director | BUY | $0.07 | 1,439,005 | $96,126 | 2,378,485 |
| 2025-03-28 01:53 | 2025-03-25 | ZYME | Zymeworks Inc. | EcoR1 Capital, LLC | Director, 10% owner | BUY | $12.61 | 97,349 | $1,227,308 | 17,255,151 |
| 2025-03-27 14:30 | 2025-03-26 | ALZN | Alzamend Neuro Inc. | Horne William B. | Director | BUY | $0.99 | 3,334 | $3,285 | 30,000 |
| 2025-03-27 02:08 | 2025-03-24 | IRON | Disc Medicine, Inc. | Ashiya Mona | Director | SELL | $54.11 | 5,738 | $310,483 | 186,541 |
| 2025-03-26 23:41 | 2025-03-24 | ARQT | Arcutis Biotherapeutics Inc. | Watanabe Todd Franklin | Director, Officer | SELL | $17.55 | 3,671 | $64,414 | 925,243 |
| 2025-03-27 00:41 | 2024-12-26 | XCUR | EXICURE, INC. | HiTron Systems Inc. | 10% owner | BUY | $3.00 | 2,900,000 | $8,700,000 | 3,333,333 |
| 2025-03-27 02:37 | 2025-03-24 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer | OPT+S | $22.50 | 1,000 | $22,505 | 23,000 |
| 2025-03-26 23:16 | 2025-03-25 | CNTA | Centessa Pharmaceuticals plc | Weinhoff Gregory M | Officer | OPT+S | $16.34 | 10,000 | $163,386 | 134,021 |
| 2025-03-26 23:05 | 2025-03-18 | HROW | HARROW, INC. | Opaleye Management Inc. | 10% owner | SELL | $30.01 | 5,000 | $150,055 | 140,000 |
| 2025-03-26 23:30 | 2025-03-25 | TRVI | Trevi Therapeutics, Inc. | SCIASCIA THOMAS | Officer | OPT+S | $6.60 | 2,631 | $17,365 | 221,373 |
| 2025-03-26 23:05 | 2025-03-25 | IMNM | Immunome Inc. | BIENAIME JEAN JACQUES | Director | BUY | $7.78 | 7,800 | $60,684 | 31,415 |
| 2025-03-26 23:03 | 2025-03-26 | IMNM | Immunome Inc. | SIEGALL CLAY B | Director, Officer | BUY | $7.29 | 137,100 | $999,459 | 806,736 |
| 2025-03-27 02:01 | 2025-03-24 | CYRX | Cryoport, Inc. | Sawicki Mark W | Officer | SELL | $6.94 | 1,349 | $9,364 | 84,087 |
| 2025-03-27 02:00 | 2025-03-24 | CYRX | Cryoport, Inc. | STEFANOVICH ROBERT | Officer | SELL | $6.94 | 1,070 | $7,428 | 190,349 |
| 2025-03-27 02:00 | 2025-03-24 | CYRX | Cryoport, Inc. | SHELTON JERRELL | Director, Officer | SELL | $6.94 | 2,980 | $20,686 | 762,419 |
| 2025-03-27 01:55 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | Lyon Joseph Douglas | Officer | OPT+S | $60.58 | 421 | $25,504 | 9,009 |
| 2025-03-27 00:07 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | BELANOFF JOSEPH K | Director, Officer | SELL | $60.83 | 1,974 | $120,084 | 3,017,437 |
| 2025-03-27 00:07 | 2025-03-24 | CORT | CORCEPT THERAPEUTICS INC | Maduck Sean | Officer | OPT+S | $60.58 | 1,697 | $102,804 | 85,622 |
| 2025-03-27 03:10 | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc. | Kihara James | Officer | OPT+S | $17.05 | 1,095 | $18,670 | 21,275 |
| 2025-03-27 03:06 | 2025-03-26 | ACAD | Acadia Pharmaceuticals Inc. | Schneyer Mark C. | Officer | OPT+S | $17.05 | 3,171 | $54,066 | 56,889 |
| 2025-03-27 02:00 | 2025-03-24 | IRON | Disc Medicine, Inc. | ORBIMED ADVISORS LLC | Director | SELL | $54.11 | 5,738 | $310,483 | 186,541 |
| 2025-03-27 00:04 | 2025-03-24 | DVAX | Dynavax Technologies Corporation | Novack David F | Officer | OPT+S | $14.00 | 10,000 | $140,000 | 8,078 |
| 2025-03-25 23:30 | 2025-03-21 | XOMA | XOMA Royalty Corp | Sitko Bradley | Officer | BUY | $23.89 | 4,134 | $98,751 | 2,800 |
| 2025-03-25 16:00 | 2025-03-24 | FGEN | KYNTRA BIO, INC. | Wettig Thane | Director, Officer | BUY | $0.35 | 145,000 | $50,663 | 543,329 |
| 2025-03-26 04:59 | 2025-03-21 | VREO | Vireo Growth Inc. | Chicago Atlantic Credit Opportunities, LLC | 10% owner | BUY | $0.43 | 25,750 | $11,132 | 384,272 |
| 2025-03-25 23:10 | 2025-03-21 | MRUS | Merus N.V. | Shuman Harry | Officer | OPT+S | $48.50 | 4,000 | $193,990 | 11,002 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.